Tests

The Role and Importance of Genetic Testing in Breast Cancer

Advanced Solutions for Hereditary Cancer Risk

The use of multi-gene testing in breast cancer diagnosis is rapidly gaining traction. But does this new generation of testing replace traditional BRCA testing? The answer to this question could have significant implications for women’s health. Research indicates that multi-gene testing provides more comprehensive information, but its full impact is still not completely understood. In this article, we’ll explore the advantages and disadvantages of multi-gene testing compared to BRCA testing.

The Rise of Multi-Gene Testing in Assessing Breast Cancer Risk

Historically, genetic testing for hereditary breast cancer has focused primarily on identifying mutations in the BRCA genes. However, the use of multi-gene tests, which assess a broader range of genetic mutations, is on the rise among women diagnosed with breast cancer. The use of tests limited to BRCA1 and BRCA2 mutations is declining. Importantly, this shift has not led to an increase in the rates of prophylactic mastectomy. Multi-gene panel tests offer patients valuable clinical insights, providing nearly twice as much information compared to tests that only assess BRCA1 and BRCA2.

Moreover, these new multi-gene tests deliver results more quickly, meaning that the evaluation of BRCA mutations no longer has to wait until after surgery.

Insights from JAMA Oncology: Breast Cancer and Genetic Testing

A study led by Dr. Allison W. Kurian, conducted between 2013 and 2015, provides critical insights into the use of genetic testing among women diagnosed with breast cancer. Here are the key findings from the study:

  • Participants and Timeframe: Over 5,000 women diagnosed with stage 0 to stage 2 breast cancer were examined between 2013 and 2015.
  • Genetic Testing Rates: Only about one-quarter of these women underwent any form of genetic testing, and this rate remained consistent over the two-year period.
  • Increase in Multi-Gene Panel Testing: In the first half of 2013, 26% of those tested underwent multi-gene panel testing. By mid-2015, this figure had risen to 66%. Conversely, the percentage of women opting for BRCA-only testing decreased from 74% to 34% during the same period.
  • Evolution of Genetic Testing: Genetic tests have become more comprehensive and affordable, highlighting a significant gap in the availability of genetic counseling services.
  • Need for Genetic Counseling and Hospital Resources: There is an increasing need for more clinical genetic counselors and hospitals that can provide timely genetic counseling services to eligible patients.

This study underscores the growing importance of genetic testing in breast cancer diagnosis and treatment, and identifies current gaps in the system. The rise in the use of multi-gene panel testing presents new opportunities for more effective use of genetic testing in breast cancer care.

The Future of Multi-Gene Testing

The increasing use of multi-gene testing signals a new era in breast cancer diagnosis and treatment. While these tests offer more comprehensive and faster results, there is also a need for the development of adequate genetic counseling services and hospital systems to support their use. Whether multi-gene testing will fully replace BRCA testing remains to be seen, and ongoing research and innovation in this area will provide clearer answers. This development could impact not only cancer patients but also their family members, making it crucial to closely monitor the effects of genetic testing in this field.

Understanding Multi-Gene Testing: A Deeper Dive

Multi-gene tests are an advanced tool used to diagnose a wide range of genetically linked diseases or conditions. Here’s a closer look at what they entail:

What Are Multi-Gene Tests?

Multi-gene tests analyze genetic variations across multiple genes using a comprehensive panel. These tests detect changes or mutations in DNA sequences that may contribute to disease.

Applications of Multi-Gene Tests

  • Disease Risk Assessment: Particularly useful for assessing the risk of genetically predisposed diseases, such as cancer.
  • Personalized Treatment Decisions: Helps tailor treatment strategies based on the specific genetic makeup of the disease.
  • Family Risk Evaluation: Assesses the risk of hereditary diseases being passed on to family members.

Technology Behind Multi-Gene Testing

These tests utilize high-throughput sequencing technologies, enabling the simultaneous analysis of numerous genes.

Advantages of Multi-Gene Testing

  • Broad Coverage: Allows for the examination of multiple genes at once, providing a comprehensive evaluation of disease risk.
  • Time and Cost Efficiency: Analyzing multiple gene mutations in a single test saves both time and money.

Potential Disadvantages

  • Uncertain Results: In some cases, the clinical significance of identified genetic variations may be unclear.
  • Ethical and Psychological Concerns: The results of these tests can pose ethical dilemmas and psychological challenges for patients and their families.

Example Application in Breast Cancer

In breast cancer, multi-gene tests can offer a broader genetic profile compared to tests focusing solely on BRCA1 and BRCA2, leading to more precise risk assessments and better-informed decisions.

Overall, multi-gene tests are a powerful tool in modern medicine, enhancing our understanding and treatment of genetically based diseases. However, the complexity and potential ethical issues associated with these tests necessitate careful consideration in their use.

The Importance of Genetic Testing in Breast Cancer Diagnosis and Treatment

Identifying a genetic predisposition plays a crucial role in the decision-making process for breast cancer diagnosis and treatment. For women with a confirmed genetic predisposition, specific algorithms guide the timing and methods of monitoring. Risk-reducing medical and surgical strategies should be objectively discussed with these women.

For example, in cases where genetic testing reveals a high risk of hereditary breast cancer, careful attention should be paid to the potential risks of other familial cancers, such as ovarian cancer. Genetic counseling is highly recommended in these scenarios.

What to Do If You Have a Family History of Breast or Ovarian Cancer

Today, clear guidelines exist for determining which patients should undergo genetic testing. One of the most important aspects is that testing should begin with the patient who has already been diagnosed. If a positive result is found, testing should be extended to first-degree relatives and potentially other family members. Key criteria include:

  • Age at Diagnosis: Genetic testing is recommended for patients diagnosed before the age of 45, regardless of other criteria. For triple-negative breast cancer, the age threshold is 65.
  • Family History: A family history of two or more cases of breast and/or ovarian cancer in first- or second-degree relatives warrants genetic counseling and testing, especially if the cancers occurred at a young age (pre-menopause), were bilateral, or were associated with other cancers such as pancreatic, colorectal, melanoma, or prostate cancer.
  • Male Breast Cancer: The presence of male breast cancer in the family is a significant criterion for genetic testing on its own.

Genetic Testing Panels in Breast Cancer

As our understanding of the genetic factors that cause breast cancer grows, so does the development of panel tests that can assess multiple genes simultaneously. Panels that include high-risk genes like BRCA1, BRCA2, p53, and PTEN, as well as lower-risk genes like ATM, CHEK2, and PARP2, are becoming more widely used. The results of these panel tests are crucial for managing the treatment process and can also guide the monitoring of other cancer types in family members.

In cases where genetic testing is not possible, or the results are inconclusive, a follow-up program should be designed based on the severity of the family history.

Interpreting Genetic Test Results in Breast Cancer

If genetic test results are negative, routine breast cancer screening should continue as usual. However, if positive, the specific mutations and associated lifetime risks must be addressed through risk-reducing strategies. These strategies fall into three categories: close monitoring, chemoprevention (risk reduction through medication), and surgical risk reduction (prophylactic mastectomy and simultaneous reconstruction). The choice of strategy should be tailored to the individual patient, considering factors such as age, the specific gene mutation, and personal preferences.

How Is Genetic Breast Cancer Identified?

Genetic analysis can determine whether an individual with breast cancer carries a genetic mutation associated with the disease. If a genetic mutation is found, all close relatives should be genetically tested to determine if they also carry the mutation.

Sometimes, genetic mutations not previously documented in medical literature may be discovered during these tests. These are known as variants of uncertain significance (VUS), and family members of individuals carrying these mutations should also be monitored.

What to Do If Breast Cancer Is Genetic

If a genetic mutation is identified in a family member with breast cancer, first-degree relatives should undergo genetic testing to determine if they carry the same mutation. If the mutation is present in a family member without cancer, the appropriate risk-reducing strategies should be discussed and implemented based on the mutation type, the patient’s age, and other relevant factors. Options may include close monitoring, prophylactic surgery, or chemoprevention.

When Should You Begin Screening If There Is a Family History of Breast Cancer?

Global guidelines recommend that family members begin screening 10 years earlier than the age at which the earliest case of breast cancer was diagnosed in the family.

A thorough risk assessment, ideally conducted by a general surgeon or breast surgeon, should include a clinical examination to create a personalized screening plan. If a genetic mutation is identified in the previous generation, genetic testing should be conducted on at-risk individuals.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button